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ABSTRACT: 
 
Canavan disease (CD) is a rare leukodystrophy characterized by diffuse spongiform 
white matter degeneration, dysmyelination and intramyelinic oedema with consequent 
impairment of psychomotor development and early death. The molecular cause of CD 
has been identified as being mutations of the gene encoding the enzyme aspartoacylase 
(ASPA) leading to its functional deficiency. The physiological role of ASPA is to 
hydrolyse N-acetyl-L-aspartic acid (NAA), producing L-aspartic acid and acetate; as a 
result, its deficiency leads to abnormally high central nervous system NAA levels. The 
aim of this article is to review what is currently known regarding the aetiopathogenesis 
and treatment of CD, with emphasis on the non-genetic therapeutic strategies, both at 
an experimental and a clinical level, by highlighting: (a) major related hypotheses, (b) 
the results of the available experimental simulatory approaches, as well as (c) the 
relevance of the so far examined markers of CD neuropathology. The potential and the 
limitations of the current non-genetic neuroprotective approaches to the treatment of 
CD are particularly discussed in the current article, in a context that could be used to 
direct future experimental and (eventually) clinical work in the field. 
 
List of abbreviations: Ac: acetate; Acetyl-CoA: acetyl-coenzyme A; ACS: acetyl-coenzyme A 
synthetase; Asp: L-aspartic acid; ASPA: aspartoacylase; AspNAT: aspartate N-acetyltransferase; BBB: 
blood-brain barrier; CA: calcium acetate; CD: Canavan disease; CNS: central nervous system; CoA: 
coenzyme A; ECF: extracellular fluid; Gln: glutamine; Glu: glutamate; GMR3: metabotropic glutamate 
receptor 3 (mGluR3); GTA: glyceryl triacetate; HPLC: high-performance liquid chromatography; Li: 
lithium; LiCl: lithium chloride; Li3C6H5O7: lithium citrate; MRI: magnetic resonance imaging; MRS: 
magnetic resonance spectroscopy; NAA: N-acetyl-L-aspartic acid or N-acetylaspartate; NAAG: N-
acetylaspartylglutamic acid; NPCs: neural progenitor cells; TCA: tricarboxylic acid    
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
3 
 
CONTENTS 
 
1. Introduction 
2. Hypotheses on the pathogenesis of CD 
3. Therapeutic approaches to CD 
4. Non-genetic therapeutic approaches to CD 
4.1. Reduction of CNS NAA levels 
4.2. Water removal 
4.3. Accumulation of NAA and oxidative stress 
4.4. Supplementation of Ac 
4.5. Energetic substrates 
4.6. Cell therapy 
4.7. Novel pharmaceutical approaches 
4.8. Blocking of NAAG catabolism 
5. Conclusion and perspectives 
Conflict of interest statement 
Acknowledgments 
References 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
4 
 
1. Introduction 
 
Canavan disease (CD), also known as the “Canavan-Van Bogaert-Bertrand” disease, is 
a rare leukodystrophy characterized by diffuse spongiform white matter degeneration, 
dysmyelination and intramyelinic oedema with consequent impairment of 
psychomotor development and early death [1-3]. Globus and Strauss [4], in 1928, were 
the first to recognise the spongy deteriorative effects of the disease, although the first 
clinical description was provided in 1931 by Myrtelle Canavan [5]. Almost two 
decades later, Van Bogaert and Bertrand [6] reported its autosomal recessive nature 
and increased prevalence amongst Ashkenazi Jewish population. The molecular cause 
of CD was identified many years later [7] as the presence of mutations within the gene 
encoding the enzyme aspartoacylase (ASPA; EC 3.5.1.15; N-acetyl-L-aspartate 
amidohydrolase) located on the short arm of chromosome 17 (17p13.3). However, 
since the purification and characterization of ASPA [8] and the cloning of the human 
ASPA cDNA [9], over 54 loss-of-function mutations have been identified [9,10]. Only 
two point mutations are responsible for 98% of the Ashkenazi Jewish cases 
(Glu285Ala and Tyr231X; CD-related mutations’ carrier rate of 1:38 to 1:59) [11-14], 
while other (non-Ashkenazi Jewish) cases may result from a range of mutations [13-
16]. The physiological role of ASPA is to hydrolyse N-acetyl-L-aspartic acid (NAA), 
producing (e.g. in oligodendrocytes) L-aspartic acid (Asp) and acetate (Ac) (see Figure 
1 for more details); as expected, its deficiency leads to abnormally high central 
nervous system (CNS) NAA levels (>35%) [17], with vast amounts of NAA being 
excreted in urine (N-acetylaspartic aciduria). It should be noted that urinary NAA 
levels are 10-100 fold higher in CD patients than age-matched healthy subjects, and 
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this is the preferred method of CD diagnosis [18]. 
Three forms of CD have been distinguished, differing in symptom onset and 
severity: (a) the “congenital form” (severest and symptoms appear within weeks of 
life), (b) the “infantile form” which is most common (also severe, with an onset of 2-6 
months) and (c) the “juvenile form” (mildest and symptoms begin by the age of 5) 
[19,20]. The “congenital” and the “juvenile” CD cases are uncommon [21]. Early 
symptoms of the disease include irritability, lack of head control and hypotonia, while 
as the disease progresses macrocephaly develops and developmental delays 
(particularly in motor and verbal skills) are noted, becoming increasingly apparent 
with age [22]. At later stages some infants may come to suffer from blindness due to 
optic atrophy, hypotonia can evolve into spasticity, voluntary movements (including 
swallowing) often become impossible and seizures may occur [23,24]. Although 
patients with some milder forms live beyond the age of 20, the majority of CD patients 
do not reach adolescence [1]. 
Neuropathologically, CD is an encephalitis periaxialis diffusa [25] where: (a) 
the failure of the white matter-seated oligodendrocytes to myelinate the local 
neuraxons leaves the latter intact but unsheathed (and, thus, underfunctioning), and (b) 
the white matter bears a characteristic spongy degeneration due to the development of 
swelling (oedema) and the formation of multiple intramyelinic and extracellular fluid 
vacuoles [26]. The vacuoles are empty, can measure up to 200 μm and are primarily 
spotted subcortically; the deep white matter and the superficial cortex are less affected. 
Macroscopically, the brain usually appears to be heavier than expected, and bears a 
soft, gelatinous white matter. Microscopically, CD patients’ brains are characterized 
by: (a) splits in the myelin lamellae and (b) astrocytic swelling (evident both in the 
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perikaryon and the processes) accompanied by elongated mitochondria [2,27-29]
1
. 
The aim of this review article is to provide an overview of the currently-
available knowledge on the aetiopathogenesis and treatment of CD, with emphasis on 
the current non-genetic approaches to its treatment at both an experimental and a 
clinical level, by highlighting: (a) the major related hypotheses, (b) the results of the 
available experimental simulatory approaches, as well as (c) the relevance of the so far 
examined markers of CD neuropathology. In particular, the potential and the 
limitations of the current non-genetic neuroprotective approaches to the treatment of 
CD are particularly discussed in the current article, in a context that could be used as a 
basis for a redrafting of both future experimental and (eventually) clinical work in the 
field. 
 
2. Hypotheses on the pathogenesis of CD 
 
Various hypotheses have attempted to explain how the lack of ASPA activity results in 
the neurodegeneration and oedema seen in CD; a result of our lack of knowledge with 
regard to the exact pathophysiological mechanisms linking the recorded ASPA 
mutations to the variable clinical presentation of CD. One of them, the “Ac-lipid-
myelin” hypothesis (Table 1) proposes that deficiency in NAA-derived Ac impedes 
myelin lipid synthesis [18,30]. Although the incorporation of acetyl moieties from 
NAA into myelin lipids has been observed [31], it is believed to be involved in - but 
not being essential to - myelination, due to documentation of rare cases of CD where 
ASPA does not function yet myelination proceeds as normal [32,33]. However, it 
                                                          
1
 for more details on the apparent oligodendrocyte number increase in the areas of dysmyelination, the 
phenotype of the astrocytic (Alzheimer Type 2) populations and/or the vacuole formation, readers are 
referred to the review article of Kumar et al. [2]. 
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should be noted that experimental evidence has suggested that ASPA is predominantly 
expressed in oligodendrocytes [34] and that the developmental expression pattern of 
the ASPA gene in the postnatal rat brain closely correlates with myelination in the 
CNS [35]. 
A second hypothesis is the “osmotic-hydrostatic” hypothesis (Table 1), which 
suggests that NAA cycling between brain cells acts as a molecular water pump, 
removing metabolic water from neurons [36]. Once produced, NAA exists in a 
complex with 32 water molecules and a cation [37]; when depolarised, neurons in grey 
matter have been shown to release this NAA complex into the surrounding 
extracellular fluid (ECF), thus transporting water against its gradient [38]. In a healthy 
subject, this complex rapidly diffuses into oligodendrocytes where it undergoes 
hydrolysis and water molecules are released [39]; this free water then diffuses down its 
concentration gradient into the vasculature [40]. However, in CD patients, the NAA-
water complex is still released upon neuronal depolarisation, but is not cleared from 
the ECF and instead diffuses into the vasculature (which has restricted permeability to 
hydrophilic molecules) [41]. The NAA-water complex builds up in the ECF which 
could lead to changes in local osmotic pressure. If a similar NAA cycle disruption 
occurs in white matter, the resulting osmotic pressure changes could account for the 
CD-related osmotic pathologies [30]. Although the depolarisation of white matter 
neurons has not been documented to cause NAA release into the ECF, it has been 
suggested that the N-acetylaspartylglutamic acid (NAAG) released from neurons 
(Figure 1) could provide a source of NAA in this case [30]. It is known that NAAG-
peptidase within the astrocyte end feet at the nodes of Ranvier hydrolyzes NAAG to 
produce NAA; this is the proposed source of NAA for white matter oligodendrocytes. 
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However, in white matter, the limited extracellular space at nodes means that a 
potential failure of oligodendrocyte removal of NAA and its consequent accumulation 
will likely have severe osmotic consequences that could explain vacuole formation and 
the observed splitting between myelin sheath layers [30]. 
A very recent third hypothesis, proposed by Francis et al. [42], is that disruption 
to NAA catabolism during key myelination stages in early development causes 
oxidative stress in myelinating oligodendrocytes resulting in dysmyelination and other 
CD-related pathologies. In this “oxidative stress” hypothesis (Table 1), NAA is 
suggested to reduce oxidative stress by preventing the coupling of fatty acid synthesis 
to oxidative energy metabolism through the provision of Ac. The latter can be 
converted to acetyl-coenzyme A (Acetyl-CoA) by acetyl-coenzyme A synthetase 
(ACS; Figure 1.c). Oxidative stress was shown to precede dysmyelination in nur7 mice 
[42] and, even more recently, Francis et al. [43] supported their hypothesis by showing 
that reduction of oxidative stress by triheptanoin administration (which increases 
Krebs cycle intermediates) was shown to alleviate CD-related pathologies.  
 
3. Therapeutic approaches to CD 
 
Due to uncertainty concerning causative mechanisms, CD is currently incurable, with 
available therapies being only palliative. Non-genetic treatment is focused principally 
on: (a) the provision of adequate hydration and nutrition, (b) the use of anticonvulsants 
to minimise seizures [1], and (c) the reduction of intracranial pressure using 
acetazolamide [22]. Research into possible therapies, including lithium (Li) 
supplementation, Ac-supplementation, stem cell replacement and gene therapy will be 
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discussed in this article, with a focus on non-genetic approaches.   
The aim of gene therapy in CD treatment is to restore ASPA activity through 
ASPA gene insertion. This approach has seen a degree of success in improving the 
major disease symptoms; however, progress is still to be made. The use of liposome 
encapsulated plasmids and adeno-associated viruses as vectors to insert the ASPA gene 
into CD mice, tremor mice and human CD subjects has resulted in enhanced ASPA 
production and activity and, in some cases, reduced CNS NAA levels and improved 
spongiform degeneration [44-48]. However, it must be noted that in some cases the 
observed decrease in NAA and spongiform pathology is transient [47], while in others 
the effects are limited within a confined area surrounding the region of intracerebral 
injection [46,47]. Improved motor function was noted in certain cases [44,47,48], but 
not in all [45]. Moreover, where motor defects were improved, they did not disappear 
altogether and were shown in a longitudinal study to relapse later in life [44]. However, 
early lethality (one of the pathologic markers of the disease) was entirely rescued by 
Ahmed et al. [44] when single intravenous injections of primate-derived adeno-
associated viruses carrying the human ASPA gene were administered as late as 
postnatal day 20 (P20) in short-lived ASPA
-/-
 mice. In fact, Ahmed et al. [44] managed 
to extend the survival of some mice to as long as 2 years; a fact that is certainly a 
significant step forward towards a gene-replacement-mediated treatment of CD.  
 
4. Non-genetic therapeutic approaches to CD 
 
The majority of the non-genetic strategies towards CD treatment employed to date 
have focused on addressing either the accumulation of NAA throughout the CNS or 
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the deficit in metabolites which results from impaired NAA hydrolysis (Figure 1). 
Both issues have been implicated in the pathological phenotype of CD, namely 
osmotic-mediated pathologies and dysmyelination. A synopsis of the major 
compounds tested as a non-genetic therapeutic approach to CD at an experimental 
and/or clinical level is provided in Table 2. 
 
4.1. Reduction of CNS NAA levels 
 
Those believing pathogenesis in CD to result principally from NAA accumulation in 
the CNS through mechanisms such as disrupted osmoregulation, have looked for 
substances that could reverse the observed CD pathology by lowering CNS NAA 
levels, determined through high-performance liquid chromatography (HPLC) analysis. 
Whilst experimental studies have identified ethanol [49,50], sodium valproate [51] as 
well as pyrazole and a number of its derivatives
2
 [49] to be potential candidates due to 
their ability to reduce NAA levels in non-diseased animal brains, when these 
compounds were tested in a CD animal model, no significant reductions were observed 
[52] (Table 2). In this case, the CD-simulating animal model used was the CD-like 
tremor rat, which possesses a CD-like syndrome as a result of a naturally-occurring 
deletion of the ASPA gene [53].  
To date, the only substance that has persistently decreased CNS NAA levels in 
both animals and humans, diseased as well as non-diseased, is Li in both the form of Li 
chloride (LiCl) and Li citrate (Li3C6H5O7)
3
. O’Donnell et al. [51] have shown LiCl to 
                                                          
2
 more specifically, the following (pyrazole-deriving) compounds which are known inhibitors of alcohol 
dehydrogenase: 4-pyrazolecarboxylic acid, 1-H-pyrazole-1-carboxamidine-HCl, 4-methypyrazole and, 
pyrazole-3,5-dicarboxylic acid monohydrate. 
3
 readers are reminded that Li compounds are used as mood stabilizing agents; their action is not yet 
characterized by a specific biochemical mechanism, but recent evidence suggests that Li might exert 
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reduce brain NAA levels by 9% when given to rats at a daily dosage of 170 mg/kg of 
body weight for 2 weeks, but it was Baslow et al. [52] that highlighted its potential 
therapeutic value in CD and tested it on CD-like tremor rats (Table 2). A 13% 
reduction in brain NAA levels was measured through HPLC analysis of CD-like 
tremor rat CNS samples following administration of LiCl at a dose of 300 mg/kg of 
body weight, daily for 4 days [52]. Interestingly, Li3C6H5O7 was later tested on a 
human CD patient [55] and achieved statistically-significant reduction of NAA levels 
in only one of the four CNS regions studied; nonetheless, NAA levels declined in all 
studied CNS regions in both the white and the grey matter, as measured through proton 
magnetic resonance spectroscopy (MRS) studies. The 18-month-old female CD patient 
ingested Li3C6H5O7 to up to 45 mg/kg of body weight per day for 4 months and her 
magnetic resonance imaging (MRI) scans showed that T1 weighted image changes in 
white matter showed greater similarity to age-matched values for healthy human 
subjects (compared with theoretical values for CD patients), suggesting that 
myelination was more normal as a result of the Li-treatment [55]. Her clinical 
symptoms also appeared mildly improved, as the patient showed increased awareness 
of her surroundings, increased alertness and minor improvement in language and gross 
motor function [55].  
A second human study on a cohort of six patients and over a time period of 60 
days [56], showed Li3C6H5O7 to be non-toxic at the same dosage (45 mg/kg per day), 
demonstrated a statistically-significant drop in NAA levels in the basal ganglia 
(through proton MRS) and indicated a mildly improved myelination in the frontal 
                                                                                                                                                                        
neuroprotection through a counteraction of mitochondrial dysfunction [54]; a potential reason for its 
herein discussed effectiveness in CD.   
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white matter (from MRI T1 relaxation times). Improved alertness and social 
interactions were also noted, while gross motor function testing on the other hand 
failed to show any statistically-significant improvement [56].  
In a more recent case report [57], Li3C6H5O7 was again reported to lower CNS 
NAA levels when given to a 3-month-old female CD patient for a year at a dosage of 
45 mg/kg per day: a 20% reduction of CNS NAA levels was achieved and the 
substance was again well-tolerated. Moreover, alertness and visual tracking were 
reported to have improved, but hypotonia and spasticity persisted [57].  
In all cases (Table 2), any symptomatic improvements from Li-administration 
were mild, but results were consistent and no adverse effects were reported following 
intake for up to a year. It is possible that higher dosages might be required to see 
greater therapeutic benefit; therefore studies on the safety of higher Li dosages in 
animals might be a beneficial prerequisite prior to any clinical attempt. The 
mechanism by which Li lowers CNS NAA levels is unknown
4
. It has been suggested 
to prevent NAA release from neurons or increase expulsion from the CNS by affecting 
blood-brain barrier (BBB) permeability [55]. An alternative mechanism that could be 
targeted is inhibition of the NAA synthetic pathways [60]. The latter could either be 
accomplished by competitive or irreversible inhibition of aspartate N-acetyltransferase 
(AspNAT; the enzyme that synthesises NAA from Asp and Acetyl-CoA) (Figure 1.c) 
or by inhibiting NAAG-peptidase in order to prevent NAA synthesis from NAAG 
hydrolysis; the latter is further discussed below.  
 
4.2. Water removal 
                                                          
4
 it is worth noting that recent experimental studies have shown that Li can enhance remyelination of 
peripheral nerves [58] and influence white matter microstructure [59] by (probably) acting as a glycogen 
synthase kinase 3-beta (GSK3-β) inhibitor. 
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Baslow and Guilfoyle [30] have recently proposed that maintenance of a sustained 
increase in plasma NAA levels in CD patients, by oral NAA-administration, might be 
therapeutic as a means of reducing oedema and other osmotic effects of the brain 
parenchyma seen in the disease. They claim that NAA accumulation in plasma would 
increase plasma oncotic pressure, and since NAA is thought to be unable to pass 
through the BBB, an outward water gradient from the CNS ECF to the vasculature 
could be established, and water could exit the brain [30]. However, studies have yet to 
be carried out to test this hypothesis.  
 
4.3. Accumulation of NAA and oxidative stress 
 
Due to evidence that CNS NAA accumulation may be damaging through its initiation 
of oxidative stress [61-63], antioxidants have been considered as a potential treatment 
for CD. Lipoic acid, known to cross the BBB and to have a high potency, was tested in 
its ability to reduce signs of NAA-induced oxidative stress in 14-day-old Wistar rats 
[64]: when given before acute NAA-administration (40 mg/kg of body weight, 
intraperitoneally, 2-days prior to NAA), all signs of oxidative stress induced by NAA 
were prevented. Whereas rats that received NAA alone showed increased lipid 
peroxidation, protein oxidation and DNA damage and decreased enzymatic and non-
enzymatic defences, none of these effects were seen in rats pre-treated with lipoic acid 
[64]. These results suggest that dietary supplementation with lipoic acid could be a 
worthwhile approach to the treatment of CD, but further studies must first produce 
evidence of symptomatic improvements in more appropriate CD animal models.   
 
4.4. Supplementation of Ac 
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Other studies have focused on the “Ac-myelin-lipid” hypothesis and attempted to 
restore myelination through Ac-supplementation [65-69] (Table 2). To this end, 
calcium Ac (CA) and glyceryl triacetate (GTA) have both been tested in their ability to 
deliver Ac to the CNS [67,68]. Intragastric administration of equivalent amounts of 
CA or GTA to 21-day-old C57BL/6 mice showed GTA to raise CNS Ac levels much 
more effectively
5
 and with fewer adverse effects than CA, although both were found to 
be reasonably safe [67,68].  
A few years later, GTA was shown to be safe when orally administered in low 
doses to CD infant patients and in high doses to tremor rat pups, although not 
efficiently alleviating the CD-associated symptomatology in the human trial [66]. A 
later study [65] on the tremor rats reported increased CNS galactocerebroside
6
 levels, 
decreased spongy vacuolation and improved motor performance due to high-dose 
administration of GTA. Moreover, once again, the treatment was well-tolerated as no 
toxic effects were reported [65].  
Given the successful tolerance of GTA at high dosage in rats, high-dose tests 
(4.5 g/kg of body weight per day) were carried out on 8-month- and 1-year-old CD 
infants over a period of 4.5 and 6 months respectively, throughout which time neither 
toxicity nor motor improvements were observed [69]. The latter was attributed to the 
late onset of treatment [69]. Moreover, it should be noted that at its highest dosage so 
far trialled, GTA has shown limited benefit in humans (Table 2), while treatment at an 
earlier age could lead to improved symptoms (as was seen in tremor rats) and should 
                                                          
5
 it has been reported that when equimolar concentrations of GTA and CA were administered 
(intragastrically) to mice, CNS Ac levels were found to be higher in the GTA-fed mice; a finding 
suggested to reflect the ability of the hydrophobic GTA to easier penetrate cell membranes [67,68]. 
6
 galactocerebroside (or galactosylceramide) is a critical CNS myelin-associated lipid that is recognised 
as an oligodendrocytic marker and that is found to be specifically-reduced in the CD-like tremor rat [70]. 
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be considered when designing future studies.  
 
4.5. Energetic substrates  
 
Another dietary supplement proposed for use as a non-genetic therapeutic approach to 
CD is the anaplerotic triglyceride “triheptanoin”. Building on the earlier observation 
that deficient NAA hydrolysis causes acute oxidative stress by increasing the coupling 
of fatty acid synthesis to oxidative energy metabolism [42], Francis et al. [43] 
attempted to restore oxidative integrity through provision of alternative substrates for 
energy production. In that study [43], nur7 mouse mutants in their last week of 
prenatal life and 2-week-old nur7 pups were fed a chow containing 35% (as caloric 
composition) triheptanoin until 12-weeks of age. Analysis of the animals’ brains at 12-
weeks showed oxidative stress, oligodendrocyte loss and dysmyelination to have been 
markedly reduced, while performance on accelerating rotarod testing at this age 
suggested improved motor function [43] (Table 2). Notably, earlier-treated mice 
showed the greatest improvements in all aforementioned parameters [43]. However, it 
is not yet known how triheptanoin supplies substrates to oligodendrocytes, but 
triheptanoin was chosen based on its ability to produce TCA cycle intermediates whilst 
also providing substrates for lipogenesis. 
 
4.6. Cell therapy 
 
Since oligodendrocytes are an important source of CNS ASPA [71], if not the most 
important [34-36,72-74], repopulation of the brain of a CD patient with functional 
oligodendrocytes could potentially rectify much of the disease phenotype through the 
restoration of normal NAA metabolism. Neural stem cells have been successfully used 
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to generate oligodendrocytes in the CD mouse model [75] and these oligodendrocytes 
expressed a myelin-specific enzyme indicative of myelin-producing ability, but clinical 
outcomes of such a treatment have yet to be investigated. Although the survival rate of 
neural progenitor cells (NPCs) was generally high in the juvenile treated mice [75], the 
migration of these cells was limited, suggesting that much progress has to be made 
before any results (if seen) will be widespread enough to impact upon the brain 
pathology of this condition. In addition to the migratory potential, the stability [76] and 
safety of transplanted and differentiated NPCs in the CD mice CNS remains to be 
proven, while acquiring sufficient quantities of NPCs for human transplantation is 
likely to be difficult [77].  
The NPCs used in the aforementioned study [75] were also tested on their 
ability to act as vectors for ASPA gene therapy. After 4 weeks of transplantation, 
enzyme activity assays carried out on juvenile CD mice showed ASPA activity to be 
16% of that measured in wild-type mice [75]. However, this activity was shown to 
decline in the adult mice 5 weeks after the transplantation, perhaps due to the short-
term expression of the retroviral vector pLXIN in vivo [75]; one should note that the 
use of adeno-associated virus vectors has been suggested to increase long-term 
efficacy of treatment. Further studies should be carried out in order to clarify whether 
ASPA activity can be sufficiently increased through this method for there to be any 
phenotypic improvement in CD mouse models. Yet again, the safety, stability, and 
migration of NPCs will still need to be considered.  
 
4.7. Novel pharmaceutical approaches 
 
The anti-convulsant “topiramate” was found to decrease the velocity of head growth in 
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two CD patients following its administration for 7 and 15 months, beginning at 6-
months of age in both children [78]. The mechanisms responsible for this effect are not 
certain, but Topçu et al. [78] suggested that CNS water accumulation was reduced, 
perhaps involving carbonic anhydrase inhibition. Although the benefit of topiramate is 
very minor to CD patients, if the underlying mechanisms by which it acts are 
elucidated, more light might be shed upon the pathological basis of the disease and 
might be supportive of the aforementioned “osmotic-hydrostatic” hypothesis. 
 
4.8. Blocking of NAAG catabolism 
 
Considering the hypothesis that an important amount of NAA accumulating within the 
white matter of CD patients could derive from NAAG catabolism, Baslow and 
Guilfoyle [60] have suggested that the use of NAAG-peptidase inhibitors or of 
metabotropic glutamate receptor 3 (GRM3 or mGluR3; the natural astrocytic surface 
target for NAAG)
7
 agonists and antagonists [79] could slow down the dysmyelination 
process. 
 
5. Conclusion and perspectives 
 
There are still many aspects of the pathophysiology of CD that need to be clarified. 
Although the intracerebral NAA accumulation and dysmyelination appear to be the 
major regulators of the disease’s progress and phenotype, experimental evidence 
suggests that CD mutations might have broader deregulating impacts on the 
developing CNS [2].  
                                                          
7
 GRM3 and NAAG-peptidase are actually a complex reported to appear particularly in the white matter 
astrocytic cells [60,79,80]. 
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It is without doubt that an efficient gene therapy for CD would be an ideal 
treatment approach if applied at a very early age. As such an approach still needs to be 
addressed through the manufacturing of long-time expression effective vectors [29], 
some degree of near-term management of CD must be considered through NAA 
synthesis-blockage or NAA removal from the patients’ CNS. At present, the only non-
genetic approach to the treatment of CD that has generated evidence towards a clinical 
improvement in CD patients is Li-supplementation. Interestingly, while drafting this 
article, Guo et al. [81] have provided a very important study in support of the 
“osmotic-hydrostatic” theory (for which Li-supplementation appears as a therapeutic 
option). On the other hand, the supplementation of Ac through GTA has shown 
promise when in animal tests, but as of yet fails to achieve clinical improvements in 
human studies, perhaps due to late onset of the attempted treatment (Table 2).  
Notably, early intervention has consistently shown to produce better results in 
all forms of treatment, supporting the theories that implicate disruption to early 
developmental myelination in the pathogenesis of CD. Targeting of oxidative stress 
seems likely to have a therapeutic benefit but clinical studies in these areas are still 
lacking. Future attempts incorporating larger cohorts, longer periods of analysis and 
wider dose schemes (especially in the case of studies focused on Li- and Ac-
supplementation) could provide more conclusive evidence of the therapeutic benefit of 
these approaches. Due to the rarity of the disease, the launching of a multicentre 
coordination initiative might be necessary in order to achieve larger cohort studies in a 
timely manner. However, even if such attempts do reach successful outcomes and 
produce a considerable clinical benefit, the course of the disease might not be fully 
obstructed until the problem is addressed at the axon-myelinating oligodendrocyte 
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interface. 
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Table 1. Overview of the current three hypotheses proposed for the pathogenesis of 
Canavan disease (CD), their mechanism(s) and the neuroprotective approaches that 
could prove effective in each case. 
 
  
Hypothesis Outline of the mechanism(s) and potential neuroprotectant(s) 
  
  
Ac-lipid-myelin  in CD patients, deficiency in NAA-derived Ac results in impeded 
myelin lipid synthesis in oligodendrocytes 
 potential therapeutic approach: CA, GTA 
  
osmotic-hydrostatic  NAA cycling between brain cells acts as a molecular water pump 
 in CD patients, the NAA-water complex builds up in the ECF, 
leading to changes in local osmotic pressure 
 in the white matter of CD patients, the limited extracellular space 
at nodes means that a potential failure of oligodendrocyte removal 
of NAA (and its consequent build up) is likely having severe 
osmotic consequences that could explain vacuole formation and 
the observed splitting between myelin sheath layers 
 potential therapeutic approach: ethanol, LiCl, Li3C6H5O7, NAA, 
pyrazole and its derivatives, sodium valproate, topiramate 
  
oxidative stress  in CD patients, disruption to NAA catabolism during key 
myelination stages in early development causes oxidative stress in 
myelinating oligodendrocytes, resulting in dysmyelination and 
other CD-related pathologies 
 potential therapeutic approach: lipoic acid, triheptanoin 
  
 
Note: the use of topiramate as a potential therapeutic approach to CD within the “osmotic-hydrostatic” 
hypothesis is still to be clarified / confirmed. Abbreviations used: Ac: acetate; CA: calcium acetate; ECF: 
extracellular fluid; GTA: glyceryl triacetate; Li: lithium; LiCl: lithium chloride; Li3C6H5O7: lithium 
citrate; NAA: N-acetyl-L-aspartic acid or N-acetylaspartate; TCA: tricarboxylic acid.  
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Table 2. Synoptic presentation of the major experimental and/or clinical studies (if any) on the efficacy of potential therapeutic 
compounds for Canavan disease (CD). 
 
   
Compound name Chemical structure Major experimental and/or clinical studies and their findings  
   
   
N-Acetyl-L-aspartate 
(NAA) 
 
 hypothesis of use: “osmotic-hydrostatic” 
 specific aim: increase of plasma NAA levels as a means of increasing plasma 
oncotic pressure and generating an outward water gradient from the CNS ECF to 
the vasculature; suggestion made by Baslow and Guilfoyle [30] 
 experimental study: --- 
 human trial: --- 
   
Calcium acetate 
(CA)  
 hypothesis of use: “Ac-lipid-myelin” 
 specific aim: Ac-supplementation towards restoration of myelination 
 experimental study: [67,68] 
 major finding(s): increased CNS Ac levels in C57BL/6 mice; less efficient than 
GTA 
   
Ethanol   hypothesis of use: “osmotic-hydrostatic” 
 specific aim: reduction of CNS NAA levels 
 experimental study: [49] 
 major finding(s): reduction of CNS NAA levels in healthy Swiss-Webster mice 
 experimental study: [52] 
 major finding(s): unable to reduce CNS NAA levels in CD-like tremor rats 
   
Glyceryl triacetate 
(GTA) 
 
 hypothesis of use: “Ac-lipid-myelin” 
 specific aim: Ac-supplementation towards restoration of myelination 
 experimental study: [67,68] 
 major finding(s): increased CNS Ac levels in C57BL/6 mice; more efficient than 
CA 
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 experimental study: [66] 
 major finding(s): no detectable toxicity due to high-dose GTA administration in 
tremor rats 
 experimental study: [65] 
 major finding(s): increased CNS galactocerebroside levels, decreased spongy 
vacuolation and improved motor performance in tremor rats due to high-dose 
administration of GTA 
 human trial: [66] 
 subject(s): two CD patients (8- and 13-month-old) 
 major finding(s): no change in CNS NAA levels, no observable pathological 
changes over the course of the treatment, stabilization of clinical condition 
without improvement 
 human trial: [69] 
 subject(s): two CD patients (8-month- and 1-year-old) 
 major finding(s): no clinical improvement, good tolerance of the high dose 
   
Lipoic acid 
 
 hypothesis of use: “oxidative stress” 
 specific aim: reduction of NAA-induced oxidative stress; crossing of the BBB 
 experimental study: [64] 
 major finding(s): reduction of NAA-induced oxidative stress-related changes in 
the Wistar rat CNS through pretreatment with lipoic acid 
   
Lithium chloride 
(LiCl) 
  hypothesis of use: “osmotic-hydrostatic” 
 specific aim: reduction of CNS NAA levels / unknown mechanism 
 experimental study: [51] 
 major finding(s): reduction of CNS NAA levels in healthy Sprague-Dawley rats 
 experimental study: [52] 
 major finding(s): reduction (-13%) of CNS NAA levels in CD-like tremor rats 
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Lithium citrate 
(Li3C6H5O7) 
 
 hypothesis of use: “osmotic-hydrostatic” 
 specific aim: reduction of CNS NAA levels / unknown mechanism 
 human trial: [55] 
 subject(s): 18-month-old female CD patient 
 major finding(s): reduction of CNS NAA levels, improved myelination, mild 
clinical improvement 
 human trial: [56] 
 subject(s): cohort of six CD patients (average age: 9.5 months) 
 major findings: reduction of basal ganglia NAA levels, mildly improved 
myelination in frontal white matter, partial clinical improvement 
 human trial: [57] 
 subject(s): 3-month-old female CD patient 
 major finding(s): reduction (-20%) of CNS NAA levels, partial clinical 
improvement 
   
Pyrazole and derivatives 
 
 hypothesis of use: “osmotic-hydrostatic” 
 specific aim: reduction of CNS NAA levels 
 experimental study: [49] 
 major finding(s): reduction of CNS NAA levels in healthy Swiss-Webster mice 
 experimental study: [52] 
 major finding(s): unable to reduce CNS NAA levels in CD-like tremor rats 
   
Sodium valproate 
 
 hypothesis of use: “osmotic-hydrostatic” 
 specific aim: reduction of CNS NAA levels 
 experimental study: [51] 
 major finding(s): reduction of CNS NAA levels in healthy Sprague-Dawley rats 
 experimental study: [52] 
 major finding(s): unable to reduce CNS NAA levels in CD-like tremor rats 
   
Topiramate 
 
 hypothesis of use: “osmotic-hydrostatic” / to be clarified 
 specific aim: presumably involving reduced CNS water accumulation due to 
carbonic anhydrase inhibition 
 human trial: [78] 
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 subject(s): two CD patients (13- and 21-month-old) 
 major finding(s): decline in head growth velocity (as a measure of 
megalencephaly progression) 
   
Triheptanoin 
 
 hypothesis of use: “oxidative stress” 
 specific aim: support of oxidative integrity, providing of ketone bodies capable of 
crossing of the BBB 
 experimental study: [43] 
 major finding(s): reduction of CNS oxidative stress, increased thalamic myelin 
levels and cortical oligodendrocyte survival, reduced spongiform degeneration as 
well as improved motor function in nur7 mice 
   
 
Abbreviations used: Ac: acetate; BBB: blood-brain barrier; CNS: central nervous system; ECF: extracellular fluid. 
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Legend to the Figure: 
 
Figure 1. Overview of the metabolic pathway of N-acetyl-L-aspartate (NAA) within 
the human central nervous system. (a, b): The synthesis of NAA occurs in neuronal 
mitochondria (1) and, from there, NAA is transported out of the mitochondria via a 
putative NAA-transporter and released from neurons or transported to 
oligodendrocytes at the junction of the neuraxon with the inner plasma membrane of 
the myelin sheaths (2). The NAA reaching the oligodendrocytes is used for fatty acid / 
myelin lipid synthesis and energy production. On the other hand, neuronal NAA could 
also combine with glutamate (Glu) to produce N-acetylaspartylglutamate (NAAG) (1). 
The latter is co-released from synaptic vesicles along with several neurotransmitters 
and can act on the astrocytic metabotropic glutamate receptor 3 (GRM3 or mGluR3) or 
be hydrolyzed at the surface of astrocytes to NAA and Glu (3). In the astrocytes, Glu 
can combine with ammonia to produce glutamine (Gln) (4). Neurons can uptake Gln 
(5) and use it as a source of Glu, while both astrocytic NAA and Gln can be released to 
the general circulation (6). (c): Schematic overview of NAA synthesis and metabolism 
in neurons and oligodendrocytes. In neuronal mitochondria, pyruvate (Pyr) undergoes 
decarboxylation by the pyruvate dehydrogenase (PDH) complex and produces acetyl-
coenzyme A (Acetyl-CoA). The latter can either be introduced to the tricarboxylic acid 
cycle (TCA cycle or Krebs cycle) or be combined with L-aspartic acid (Asp) to 
synthesize NAA via aspartate N-acetyltransferase (AspNAT). One NAA is transferred 
out of the neuronal mitochondrion, it can either be used to synthesize NAAG, to be 
released from the neurons or to be transferred to the oligodendrocytes. In the 
oligodendrocytes, NAA is hydrolyzed by aspartoacylase (ASPA; the enzyme whose 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
35 
 
deficiency is considered as the causing factor for Canavan disease) to produce Asp and 
acetate (Ac). The latter can be converted to Acetyl-CoA by acetyl-coenzyme A 
synthetase (ACS) which in turn can provide a substrate for the synthesis of fatty acid 
synthesis and myelination. Figure based on data from: Baslow and Guilfoyle [60], 
Benarroch [82], Hoshino and Kubota [1] and Moffett et al. [83].  
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[ Figure 1 ] 
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HIGHLIGHTS: 
 Canavan disease (CD) is a rare leukodystrophy primarily affecting infants.  
 The molecular cause of CD is mutations of the gene encoding aspartoacylase 
(ASPA).  
 Functional deficiency of ASPA causes brain N-acetyl-L-aspartic acid accumulation.  
 The aetiopathogenesis and treatment of CD are reviewed. 
 Potential and limitations of non-genetic approaches to the treatment of CD are 
discussed. 
